Eventide Healthcare & Life Sciences I
Name
Price
Aum/Mkt Cap
YIELD & DIV
Exp Ratio
Watchlist
Vitals
YTD Return
-20.6%
1 yr return
-38.5%
3 Yr Avg Return
-3.5%
5 Yr Avg Return
9.4%
Net Assets
$1.25 B
Holdings in Top 10
43.0%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 1.29%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 62.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
$100,000
IRA
N/A
Fund Classification
Fund Type
Open End Mutual Fund
Investment Style
Health
Name
Price
Aum/Mkt Cap
YIELD & DIV
Exp Ratio
Watchlist
ETIHX - Profile
Distributions
- YTD Total Return -20.6%
- 3 Yr Annualized Total Return -3.5%
- 5 Yr Annualized Total Return 9.4%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -1.28%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Annually
Fund Details
-
Legal NameEventide Healthcare & Life Sciences Fund
-
Fund Family NameEventide Funds
-
Inception DateDec 27, 2012
-
Shares OutstandingN/A
-
Share ClassInst
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerFinny Kuruvilla
Fund Description
Under normal market conditions, the fund invests at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.
ETIHX - Performance
Return Ranking - Trailing
| Period | ETIHX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -20.6% | -29.0% | 25.3% | 92.15% |
| 1 Yr | -38.5% | -60.2% | 11.7% | 93.64% |
| 3 Yr | -3.5%* | -10.0% | 19.7% | 95.30% |
| 5 Yr | 9.4%* | -6.4% | 16.9% | 56.64% |
| 10 Yr | N/A* | 6.4% | 18.5% | N/A |
* Annualized
Return Ranking - Calendar
| Period | ETIHX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2021 | -25.2% | -79.9% | 24.2% | 93.06% |
| 2020 | 32.5% | -13.6% | 178.2% | 11.11% |
| 2019 | 55.4% | 3.8% | 63.8% | 1.38% |
| 2018 | -6.9% | -49.7% | 21.5% | 45.99% |
| 2017 | 43.9% | -59.8% | 54.4% | 2.96% |
Total Return Ranking - Trailing
| Period | ETIHX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -20.6% | -46.5% | 25.3% | 83.77% |
| 1 Yr | -38.5% | -60.2% | 28.3% | 94.27% |
| 3 Yr | -3.5%* | -13.2% | 20.0% | 94.51% |
| 5 Yr | 9.4%* | -6.4% | 16.9% | 55.70% |
| 10 Yr | N/A* | 6.4% | 18.5% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | ETIHX Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2021 | -25.2% | -79.9% | 24.2% | 93.06% |
| 2020 | 32.5% | -13.6% | 178.2% | 11.11% |
| 2019 | 55.4% | 3.8% | 63.8% | 1.38% |
| 2018 | -6.9% | -49.7% | 22.2% | 52.55% |
| 2017 | 45.8% | -59.8% | 54.4% | 2.22% |
NAV & Total Return History
ETIHX - Holdings
Concentration Analysis
| ETIHX | Category Low | Category High | ETIHX % Rank | |
|---|---|---|---|---|
| Net Assets | 1.25 B | 732 K | 46.2 B | 37.37% |
| Number of Holdings | 71 | 21 | 473 | 47.62% |
| Net Assets in Top 10 | 683 M | 2.18 K | 21.6 B | 26.19% |
| Weighting of Top 10 | 42.97% | 12.3% | 80.8% | 57.62% |
Top 10 Holdings
- Prometheus Biosciences Inc 7.68%
- Karuna Therapeutics Inc 5.97%
- Biohaven Pharmaceutical Holding Co Ltd 5.59%
- MyoKardia Inc 4.95%
- Zymeworks Inc Registered Shs When Issued 4.89%
- argenx SE ADR 4.56%
- Ascendis Pharma A/S ADR 4.24%
- Trillium Therapeutics Inc 4.15%
- Sarepta Therapeutics Inc 3.87%
- Us Bank Mmda - Usbgfs5 3.58%
Asset Allocation
| Weighting | Return Low | Return High | ETIHX % Rank | |
|---|---|---|---|---|
| Stocks | 85.37% | 85.37% | 106.13% | 99.05% |
| Preferred Stocks | 7.23% | 0.00% | 7.86% | 1.90% |
| Cash | 5.73% | -0.10% | 9.01% | 5.71% |
| Other | 1.65% | -22.99% | 3.38% | 9.05% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 25.71% |
| Bonds | 0.00% | 0.00% | 12.39% | 22.38% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | ETIHX % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 10.48% |
| Utilities | 0.00% | 0.00% | 0.00% | 20.00% |
| Technology | 0.00% | 0.00% | 22.69% | 25.71% |
| Real Estate | 0.00% | 0.00% | 7.13% | 24.76% |
| Industrials | 0.00% | 0.00% | 7.02% | 25.71% |
| Financial Services | 0.00% | 0.00% | 1.85% | 38.10% |
| Energy | 0.00% | 0.00% | 0.00% | 20.00% |
| Communication Services | 0.00% | 0.00% | 9.11% | 23.33% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 29.05% |
| Consumer Cyclical | 0.00% | 0.00% | 14.20% | 24.29% |
| Basic Materials | 0.00% | 0.00% | 14.83% | 42.86% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | ETIHX % Rank | |
|---|---|---|---|---|
| US | 72.16% | 53.67% | 104.41% | 87.62% |
| Non US | 13.21% | 0.00% | 45.40% | 44.29% |
ETIHX - Expenses
Operational Fees
| ETIHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 1.29% | 0.08% | 3.13% | 24.41% |
| Management Fee | 1.10% | 0.00% | 1.25% | 94.21% |
| 12b-1 Fee | 0.00% | 0.00% | 1.00% | 9.09% |
| Administrative Fee | N/A | 0.03% | 0.25% | 22.45% |
Sales Fees
| ETIHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 0.00% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| ETIHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 2.00% | 62.50% |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| ETIHX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 62.00% | 0.00% | 238.00% | 78.95% |
ETIHX - Distributions
Dividend Yield Analysis
| ETIHX | Category Low | Category High | ETIHX % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.00% | 0.00% | 3.95% | 29.77% |
Dividend Distribution Analysis
| ETIHX | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | Annually | Annually | Semi-Annually | Annually |
Net Income Ratio Analysis
| ETIHX | Category Low | Category High | ETIHX % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -1.28% | -2.54% | 1.92% | 93.71% |
Capital Gain Distribution Analysis
| ETIHX | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
ETIHX - Fund Manager Analysis
Managers
Finny Kuruvilla
Start Date
Tenure
Tenure Rank
Dec 27, 2012
9.43
9.4%
Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.54 | 2.12 |